Please login to the form below

Not currently logged in
Email:
Password:

tremelimumab,

This page shows the latest tremelimumab, news and features for those working in and with pharma, biotech and healthcare.

AZ swells immuno-oncology pipeline with Innate deal

AZ swells immuno-oncology pipeline with Innate deal

two primary endpoints in the MYSTIC trial of Imfinzi plus AZ’s experimental CTLA4 inhibitor tremelimumab in first-line lung cancer treatment.

Latest news

More from news
Approximately 5 fully matching, plus 44 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    For instance, AZ’s MYSTIC of Imfinzi and CTLA4 drug tremelimumab in lung cancer wasn’t able to impact progression-free survival and – while the company is still hoping to show

  • Pharma deals during July 2014 Pharma deals during July 2014

    tremelimumab. Existing partners Bristol-Myers Squibb (BMS) and Ono Pharmaceutical also announced that they will jointly develop and commercialise multiple immunotherapies as single and combination treatments.

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    2 trials for NSCLC, and tremelimumab, an anti-CTLA4 MAb in phase 2 for the rare cancer mesothelioma. “

  • Pharma deals during August 2013 Pharma deals during August 2013

    The $500m acquisition of Amplimmune marries well with Medimmune's existing commitment to cancer immunotherapy, which includes not only the anti-PD1 mAB MEDI-4736 but also tremelimumab (CLTA-4 mAB)

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...

Infographics